Esperion Therapeutics, Inc. (ESPR)
ESPR Stock Price Chart
Explore Esperion Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ESPR price movements and trends.
ESPR Company Profile
Discover essential business fundamentals and corporate details for Esperion Therapeutics, Inc. (ESPR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
26 Jun 2013
Employees
304.00
Website
https://www.esperion.comCEO
Sheldon L. Koenig
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
ESPR Financial Timeline
Browse a chronological timeline of Esperion Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 2 Mar 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.06, while revenue estimate is $78.33M.
Earnings released on 5 Aug 2025
EPS came in at -$0.02 surpassing the estimated -$0.17 by +88.24%, while revenue for the quarter reached $82.39M , missing expectations by -0.10%.
Earnings released on 6 May 2025
EPS came in at -$0.21 falling short of the estimated -$0.18 by -16.67%, while revenue for the quarter reached $65.00M , beating expectations by +6.15%.
Earnings released on 4 Mar 2025
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $69.11M , beating expectations by +33.68%.
Earnings released on 7 Nov 2024
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%, while revenue for the quarter reached $51.63M , missing expectations by -16.12%.
Earnings released on 12 Aug 2024
EPS came in at -$0.05 surpassing the estimated -$0.15 by +66.67%, while revenue for the quarter reached $73.83M , beating expectations by +50.50%.
Earnings released on 7 May 2024
EPS came in at $0.34 surpassing the estimated $0.05 by +580.00%, while revenue for the quarter reached $137.74M , beating expectations by +62.98%.
Earnings released on 27 Feb 2024
EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%, while revenue for the quarter reached $32.25M , beating expectations by +12.37%.
Earnings released on 7 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.42 by +11.90%, while revenue for the quarter reached $33.97M , beating expectations by +14.84%.
Earnings released on 1 Aug 2023
EPS came in at -$0.46 surpassing the estimated -$0.63 by +26.98%, while revenue for the quarter reached $25.79M , beating expectations by +4.65%.
Earnings released on 9 May 2023
EPS came in at -$0.79 falling short of the estimated -$0.65 by -21.54%, while revenue for the quarter reached $24.33M , beating expectations by +10.54%.
Earnings released on 21 Feb 2023
EPS came in at -$0.76 surpassing the estimated -$0.87 by +12.64%, while revenue for the quarter reached $18.82M , missing expectations by -8.69%.
Earnings released on 1 Nov 2022
EPS came in at -$0.81 surpassing the estimated -$0.93 by +12.90%, while revenue for the quarter reached $18.98M , missing expectations by -3.57%.
Earnings released on 2 Aug 2022
EPS came in at -$1.05 falling short of the estimated -$0.95 by -10.53%, while revenue for the quarter reached $18.84M , beating expectations by +1.21%.
Earnings released on 3 May 2022
EPS came in at -$0.93 surpassing the estimated -$0.96 by +3.12%, while revenue for the quarter reached $18.84M , beating expectations by +22.26%.
Earnings released on 22 Feb 2022
EPS came in at -$1.77 surpassing the estimated -$2.32 by +23.71%, while revenue for the quarter reached $15.40M , beating expectations by +6.36%.
Earnings released on 2 Nov 2021
EPS came in at -$2.62 surpassing the estimated -$2.86 by +8.39%, while revenue for the quarter reached $14.41M , missing expectations by -12.83%.
Earnings released on 3 Aug 2021
EPS came in at -$1.67 surpassing the estimated -$1.82 by +8.24%, while revenue for the quarter reached $40.66M , meeting expectations.
Earnings released on 4 May 2021
EPS came in at -$3.50 falling short of the estimated -$2.08 by -68.27%, while revenue for the quarter reached $7.98M , missing expectations by -76.72%.
Earnings released on 23 Feb 2021
EPS came in at -$3.89 falling short of the estimated -$3.76 by -3.46%, while revenue for the quarter reached $9.64M , missing expectations by -43.27%.
Earnings released on 2 Nov 2020
EPS came in at -$3.07 surpassing the estimated -$3.52 by +12.78%, while revenue for the quarter reached $3.83M , missing expectations by -10.76%.
ESPR Stock Performance
Access detailed ESPR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.